To access prescribing  information for Janssen products not listed click prescribing information

PRESCRIBING INFORMATION

Alphabetical by Janssen brand name

DARZALEX® 20 mg/ml concentrate for solution for infusion

ACTIVE INGREDIENT(s): daratumumab

Click to view DARZALEX® prescribing information

 

EDURANT® 25 mg film-coated tablet

ACTIVE INGREDIENT(s): rilpivirine

Click to view EDURANT® prescribing information

 

IMBRUVICA® 140mg hard capsules

ACTIVE INGREDIENT(s): ibrutinib

Click to view IMBRUVICA® prescribing information

 

INTELENCE® 25 mg, 100 mg & 200 mg tablets

ACTIVE INGREDIENT(s): etravirine

Click to view INTELENCE® prescribing information

 

INVEGA® 3 mg, 6 mg, 9 mg and 12 mg prolonged-release tablets

ACTIVE INGREDIENT(s): paliperidone

Click to view INVEGA® prescribing information

 

PREZISTA® 100mg/ml oral suspension and 75mg, 150mg, 400mg, 600mg and 800mg film-coated tablets

ACTIVE INGREDIENT(s): darunavir

Click to view PREZISTA® prescribing information

PREZISTA 100 mg/ml oral suspension

PREZISTA 75 mg film-coated tablets

PREZISTA 150 mg film-coated tablets

PREZISTA 400 mg film-coated tablets

PREZISTA 600 mg film-coated tablets

PREZISTA 800 mg film coated tablets

 

REZOLSTA® 800 mg/150 mg film-coated tablets

ACTIVE INGREDIENT(s): darunavir and cobicistat

Click to view REZOLSTA® prescribing information

 

RISPERDAL® CONSTA® 25mg, 37.5mg and 50mg injection

ACTIVE INGREDIENT(s): risperidone

Click to view RISPERDAL®CONSTA® prescribing information

RISPERDAL® CONSTA® 25 mg injection

RISPERDAL® CONSTA® 37.5 mg injection

RISPERDAL® CONSTA® 50 mg injection

 

RISPERDAL® film-coated tablets and oral solution

ACTIVE INGREDIENT(s): risperidone

Click to view RISPERDAL® film-coated tablets and oral solution prescribing information

RISPERDAL 0.5 mg film-coated tablets

RISPERDAL 1 mg film-coated tablets

RISPERDAL 2 mg film-coated tablets

RISPERDAL 3 mg film-coated tablets

RISPERDAL 4 mg film-coated tablets

RISPERDAL 6 mg film-coated tablets

 

STELARA® concentrate for solution for infusion, solution for injection (vial) and solution for injection in pre-filled syringe

ACTIVE INGREDIENT(s): ustekinumab

Click to view STELARA® prescribing information

STELARA 130 mg concentrate for solution for infusion

STELARA 45 mg and 90 mg solution for injection (vial) and solution for injection in pre filled syringe

 

 

TREVICTA® 175 mg, 263 mg, 350 mg & 525 mg prolonged release suspension for injection

ACTIVE INGREDIENT(s): paliperidone palmitate

Click to view TREVICTA® prescribing information

 

VELCADE® 3.5 mg powder for solution for injection

ACTIVE INGREDIENT(s): bortezomib

Click to view VELCADE® prescribing information

 

XEPLION® 25 mg, 50 mg, 75 mg, 100 mg & 150 mg prolonged-release suspension for injection

ACTIVE INGREDIENT(s): paliperidone palmitate

Click to view XEPLION® prescribing information

 

ZYTIGA® 500 mg Tablets

ACTIVE INGREDIENT(s): abiraterone acetate

Click to view ZYTIGA® prescribing information

ZYTIGA 500 mg film-coated tablets

 

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse reactions related to this medicinal product. Reporting forms and information can be found at www.HPRA.IE. Adverse events should also be reported to Janssen-Cilag Limited on 001494 567447 or at [email protected].

 

Content Date of Preparation: August 2017
Item code: PHIR/NPR/0817/0001h